ArriVent BioPharma, Inc. Common Stock
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. Total operating expenses were $74,590,000.
Profit Margin
| 2023 | 0 | -69.33M |
|---|
AVBP Income Statement (2023 – 2023)
| 2023 | |
|---|---|
Revenue | |
Revenue | 0 |
Cost of revenue | 0 |
Gross profit | 0 |
Operating exp. | |
Research and development | 64.88M |
Selling and marketing | 0 |
Total operating expenses | 74.59M |
Operating income | -74.59M |
Other income (expenses), net | 5.25M |
Income before tax | -69.33M |
Income tax expense | 0 |
Net income | -69.33M |
Earnings per share | |
Basic EPS | -2.17 |
Diluted EPS | -2.17 |